Topotarget announces the date for the Q1 2010 interim report and a related telephone conference

To NASDAQ OMX Copenhagen A/S
Investor News No. 04-10 / Copenhagen, 18 May, 2010

Topotarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com


Copenhagen, Denmark - 18 May 2010 - Topotarget A/S (OMX: TOPO) announces that
the interim report for Q1 2010 will be released on 20 May 2010. On the same day
a teleconference will be held at 2 pm local time, where CEO Francois Martelet
and CFO Anders Vadsholt will present the 2010 Q1 interim report and answer
questions. The teleconference will be conducted in English. A presentation will
be available on Topotarget's website, www.topotarget.com, before the start of
the conference call. 
To participate in the conference call please dial:
- From Denmark: 32 71 47 67
- Outside Denmark: +45 70 26 50 40 or +44 800 634 5205 (UK) or +1 866 629 2704
(US) or +46 200 125 785 (SE) Confirmation Number 2854904. 
A replay of the conference call will be available approximately two hours after
the conference call and until 27 May, 2010 at: +353 1 436 4267, pin code:
2854904#. From 27 May 2010 to 23 September 2010 a replay will be available on
the Topotarget homepage www.topotarget.com 
Topotarget A/S
For further information, please contact:
Francois Martelet, CEO: Direct: +45 39 17 94 99; Mobile: +45 31 36 83 41
Anders Vadsholt, CFO: Direct: +45 39 17 83 45; Mobile: +45 28 98 90 55
Page 1 of 2
Topotarget announces the date for the Q1
2010 interim report and a related telephone
conference
Investor News No. 04-10 Page 2 of 2
Background information
About Topotarget
Topotarget (NASDAQ OMX: TOPO) is an international biotech company headquartered
in Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. Topotarget currently focuses, in collaboration with Spectrum
Pharmaceuticals, Inc., on the development in pivotal studies of its lead drug
candidate, belinostat, which has shown proof-of-concept as monotherapy in
treating haematological malignancies and positive results in solid tumours.
Belinostat can be used in combination with full doses of chemotherapy, and is
currently in a pivotal trial within PTCL (peripheral T-cell lymphoma).
Topotarget's key cancer drugs target HDAC, NAD+, mTOR, Fas ligand and
topoisomerase II. The company's first marketed product, Savene®/Totect®, was
approved by EMEA in 2006 and the FDA in 2007, and is marketed by Topotarget's
own sales force in the US. For more information, please refer to
www.topotarget.com. 
Topotarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.